ArticleEClinicalMedicine2023
The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations.
Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- ASO Author Reflections: Refining Postoperative Management for Stage IA EGFR-Mutated Lung Adenocarcinoma: Toward Risk-Adapted Adjuvant Therapy.Annals of surgical oncology · 2026Article
- The Efficacy of Adjuvant EGFR-TKI Therapy for Stage IA Lung Adenocarcinoma with EGFR Mutations: A Retrospective Cohort Study.Annals of surgical oncology · 2026Article
- The clinicoradiological and pathological-molecular characteristics associated with spread through air spaces in stage IA invasive lung adenocarcinoma.Insights into imaging · 2026Article
- Adjuvant targeted therapy in high-risk stage IB epidermal growth factor receptor-mutant lung cancer: Role of ground-glass opacity components.JTCVS open · 2026Article
- Utilizing clinical features, genetic mutations, and a 14-gene molecular assay for optimizing the management of multiple primary lung cancer.Translational lung cancer research · 2026Article
- Computed Tomography-Pathology Deep Learning Model for the Precise Prediction of Recurrence in Pathological Stage IA Lung Adenocarcinoma.Annals of surgical oncology · 2026Article
- Targeted therapy for stage IA non-small cell lung cancer withTranslational lung cancer research · 2026Review
- Air pollution, driver mutations, and survival in non-small cell lung cancer: insights from a high-altitude Hispanic cohort.Translational lung cancer research · 2026Article
- Sublobar resection combined with furmonertinib in peripheral solid EGFR-mutated stage IA3 lung adenocarcinoma patients with pulmonary dysfunction: a retrospective multi-institutional study.Journal of thoracic disease · 2026Article
- A lung microbial signature for postoperative recurrence in stage I-II non-small cell lung cancer.Respiratory research · 2026Article
- Article
- Imaging appearances, CT evolution patterns, and surgical prognosis of stage I lung squamous cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Real-world efficacy of postoperative adjuvant EGFR-TKI therapy for stage IA2-IA3 lung adenocarcinoma with high-risk pathological factors.World journal of surgical oncology · 2025Article
- The characteristics and prognoses of 72 postoperative synchronous multiple primary lung cancer patients.World journal of surgical oncology · 2025Article
- Accurate prediction of disease-free and overall survival in non-small cell lung cancer using patient-level multimodal weakly supervised learning.NPJ precision oncology · 2025Article
- Impact of DNA methylation on the recurrence risk of stage I non-small cell lung cancer with EGFR mutations.Clinical epigenetics · 2025Article
- Clinicopathological factorsTranslational lung cancer research · 2025Article
- Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series.PloS one · 2025Article
- Value of the 14-gene molecular assay in efficacy assessment of neoadjuvant chemoimmunotherapy for non-small cell lung cancer.Frontiers in molecular biosciences · 2025Article
- Risk Stratification and Adjuvant Chemotherapy for High-Risk Stage IA Lung Adenocarcinoma: The Unmet Needs.Thoracic cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, the role of EGFR-TKIs as adjuvant therapy for stage I, especially IA NSCLC, after surgical resection remains unclear. We aimed to compare the effect of adjuvant EGFR-TKIs with observation in such patients by incorporating an established 14-gene molecular assay for risk stratification. Methods: This retrospective cohort study was conducted at the First Affiliated Hospital of Guangzhou Medical University (Study ID: ChNCRCRD-2022-GZ01). From March 2013 to February 2019, completely resected stage I NSCLC (8th TNM staging) patients with sensitive EGFR mutation were included. Patients with eligible samples for molecular risk stratification were subjected to the 14-gene prognostic assay. Inverse probability of treatment weighting (IPTW) was employed to minimize imbalances in baseline characteristics. Findings: A total of 227 stage I NSCLC patients were enrolled, with 55 in EGFR-TKI group and 172 in the observation group. The median duration of follow-up was 78.4 months. After IPTW, the 5-year DFS (HR = 0.30, 95% CI, 0.14-0.67; P = 0.003) and OS (HR = 0.26, 95% CI, 0.07-0.96; P = 0.044) of the EGFR-TKI group were significantly better than the observation group. For subgroup analyses, adjuvant EGFR-TKIs were associated with favorable 5-year DFS rates in both IA (100.0% vs. 84.5%; P = 0.007), and IB group (98.8% vs. 75.3%; P = 0.008). The 14-gene assay was performed in 180 patients. Among intermediate-high-risk patients, EGFR-TKIs were associated with a significant improvement in 5-year DFS rates compared to observation (96.0% vs. 70.5%; P = 0.012), while no difference was found in low-risk patients (100.0% vs. 94.9%; P = 0.360). Interpretation: Our study suggested that adjuvant EGFR-TKI might improve DFS and OS of stage IA and IB EGFR-mutated NSCLC, and the 14-gene molecular assay could help patients that would benefit the most from treatment. Funding: This work was supported by China National Science Foundation (82022048, 82373121).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.